Sign Up Today and Learn More About Initial Therapeutics Stock
Invest in or calculate the value of your shares in Initial Therapeutics or other pre-IPO companies through EquityZen's platform.
Initial Therapeutics Stock (INTH)
Initial Therapeutics is a developer of small-molecule medicines designed to prevent pathogenic protein synthesis.
About Initial Therapeutics Stock
Founded
2020
Headquarters
New York, NY, US
Industries
Science and Engineering, Health Care, Biotechnology
Initial Therapeutics Press Mentions
Stay in the know about the latest news on Initial Therapeutics
Compounds, Compositions and Methods for Attenuation of Mammalian Translation of …
patents • Apr 02, 2025
Compounds, compositions and methods for attenuation of mammalian translation of …
patents • Feb 10, 2025
Research Institute Bio-Assay Development jobs in United States | by Relevance
biospace • Jun 25, 2024
Initial Therapeutics on LinkedIn: Excited to welcome our new CEO Peter DiLaura ! https://lnkd.in/eCb9Tr7j | 18 comments
linkedin • Jun 25, 2024
Startup launched by 3 UC scientists, including husband of Nobel laureate Jennifer Doudna, hires CEO - San Francisco ...
bizjournals • May 20, 2024
Initial Therapeutics Management
Leadership team at Initial Therapeutics
Board Member
Raj Chopra
Chief Executive Officer & Board Member
Spiros Liras
Join now and verify your accreditation status to gain access to:
- Initial Therapeutics Current Valuation
- Initial Therapeutics Stock Price
- Initial Therapeutics Management
- Available deals in Initial Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Initial Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Initial Therapeutics Revenue and Financials
- Initial Therapeutics Highlights
- Initial Therapeutics Business Model
- Initial Therapeutics Risk Factors
- Initial Therapeutics Research Report from SACRA Research
Trading Initial Therapeutics Stock
How to invest in Initial Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Initial Therapeutics through EquityZen funds. These investments are made available by existing Initial Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Initial Therapeutics stock?
Shareholders can sell their Initial Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 380K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 47K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
